Vascular Biogenics Ltd. (VBLT)
VBLTPrice: $0.16
Fair Value: 🔒
🔒score
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vesse... more
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the t... more
Description
Shares
| Market Cap | $12.11M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | IL | CEO | Dror Harats |
| IPO Date | 2014-10-01 | CAGR | — |
| Employees | 7 | Website | www.vblrx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
VBLT chart loading...
Fundamentals
Technicals
| Enterprise Value | $12.36M | P/E Ratio | -0.87 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 7.72 | P/B Ratio | 0.04 |
| P/CF Ratio | -0.04 | P/FCF Ratio | -0.17 |
| EPS | $-0.18 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -86.77% | Gross Margin | 0.36% |
| Operating Margin | -47.28% | Profit Margin | -36.34% |
| ROE | 1.03% | ROA | -0.58% |
| ROCE | -0.87% | Current Ratio | 5.65 |
| Quick Ratio | 4.6 | Cash Ratio | 4.32 |
| Debt/Equity | 0.14 | Interest Coverage | — |
| Altman Z Score | -19.93 | Piotroski Score | — |